Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report-Reference-Cited by-同舟云学术

Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report

Published:2023-06 Issue:6 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Camus Vincent¹^ORCID,Etancelin Pascaline²,Drieux Fanny³,Veresezan Elena‐Liana³,Picquenot Jean‐Michel³,Penther Dominique²,Viennot Mathieu⁴,Ruminy Philippe⁴,Contentin Nathalie¹,Lemasle Emilie¹,Leprêtre Stéphane¹,Dubois Sydney¹,Penichoux Juliette¹,Stamatoullas Aspasia¹,Zduniak Alexandra¹,Lanic Hélène¹,Jardin Fabrice¹

Affiliation:

1. Department of Hematology Centre Henri Becquerel Rouen France

2. Department of Genetic Oncology Centre Henri Becquerel Rouen France

3. Department of Pathology Centre Henri Becquerel Rouen France

4. INSERM U1245 Centre Henri Becquerel Rouen France

Abstract

Key Clinical MessageThis case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T‐cell lymphomas, for which effective therapies are still scarce.AbstractPeripheral T‐cell lymphomas have an aggressive disease course associated with poor outcomes. We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T‐cell lymphoma (angioimmunoblastic‐type [nTFHL‐AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy. The complete hematologic response achieved has lasted more than 2 years.

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.7623

Reference28 articles.

1. Peripheral T-cell Lymphomas

2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

3. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond

4. Peripheral T-Cell Lymphomas: Therapeutic Approaches

5. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study